Cart
Inhibitory Antibodies

Inhibitory Antibodies

A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.

The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.

After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.

Targetmol provides 30 monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.

Cat No. Product Name
T9901 Adalimumab (anti-TNF-alpha) Adalimumab (anti-TNF-alpha) is the first fully human, recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.
T9902 Atezolizumab (anti-PD-L1) Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction o...
T9903 Avelumab (anti- PD-L1) Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
T9904 Bevacizumab(anti-VEGF) Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
T9905 Cetuximab (anti-EGFR) Cetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).
T9906 Ipilimumab (anti-CTLA-4) Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibi...
T9907 Nivolumab (anti-PD-1) Nivolumab (anti-PD-1) is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human c...
T9908 Pembrolizumab (anti-PD-1) Pembrolizumab is a humanized antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
T9909 Pertuzumab (anti-HER2) Pertuzumab (anti-HER2), a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER...
T9910 Rituximab (anti-CD20) Rituximab (anti-CD20) is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM.
T9911 Tocilizumab (anti-IL-6R) Tocilizumab (anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor
T9912 Trastuzumab (anti-HER2) Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HE...
T9913 Ustekinumab Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.
T9914 Vedolizumab Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
T9915 Eculizumab Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5
T9916 Alirocumab Alirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture.
T9917 Denosumab Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand
T9918 Daratumumab Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells.
T9919 Alemtuzumab Alemtuzumab is a humanized monoclonal antibody against CD52, an antigen found on the surface of normal and malignant lymphocytes.
T9920 Evolocumab Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9).
T9921 Infliximab Infliximab is a humanized antibody against tumor necrosis factor α (TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis.
T9922 Matuzumab Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR, frequently associated with the growth of blood vessels i...
T9923 Nimotuzumab Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR).
T9924 Obinutuzumab/afutuzumab Obinutuzumab (GA101) a novel glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.
T9925 Ofatumumab Ofatumumab is a fully human monoclonal antibody to CD20, which appears to inhibit early-stage B lymphocyte activation
T9926 Omalizumab Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE)
T9927 Panitumumab Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor (EGFR).
T9928 Ranibizumab Ranibizumab is an antibody fragment without the Fc portion and affinity-matured to more strongly bind VEGF-A
T9929 Ramucirumab Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors.
T9930 Secukinumab Secukinumab is a fully humanized, monoclonal anti-IL-17A antibody, and the first in its class to be approved by the US Food and Drug Administration for the trea...
Adalimumab (anti-TNF-alpha)
T9901CAS 331731-18-1
Adalimumab (anti-TNF-alpha) is the first fully human, recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.
Atezolizumab (anti-PD-L1)
T9902CAS 1380723-44-3
Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction o...
Avelumab (anti- PD-L1)
T9903CAS 1537032-82-8
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
Bevacizumab(anti-VEGF)
T9904CAS 216974-75-3
Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
Cetuximab (anti-EGFR)
T9905CAS 205923-56-4
Cetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).
Ipilimumab (anti-CTLA-4)
T9906CAS 477202-00-9
Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibi...
Nivolumab (anti-PD-1)
T9907CAS 946414-94-4
Nivolumab (anti-PD-1) is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human c...
Pembrolizumab (anti-PD-1)
T9908CAS 1374853-91-4
Pembrolizumab is a humanized antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
Pertuzumab (anti-HER2)
T9909CAS 380610-27-5
Pertuzumab (anti-HER2), a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER...
Rituximab (anti-CD20)
T9910CAS 174722-31-7
Rituximab (anti-CD20) is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM.
Tocilizumab (anti-IL-6R)
T9911CAS 375823-41-9
Tocilizumab (anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor
Trastuzumab (anti-HER2)
T9912CAS 180288-69-1
Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HE...
Ustekinumab
T9913CAS 815610-63-0
Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.
Vedolizumab
T9914CAS 943609-66-3
Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
Eculizumab
T9915CAS 219685-50-4
Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5
Alirocumab
T9916CAS 1245916-14-6
Alirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture.
Denosumab
T9917CAS 615258-40-7
Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand
Daratumumab
T9918CAS 945721-28-8
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells.
Alemtuzumab
T9919CAS 216503-57-0
Alemtuzumab is a humanized monoclonal antibody against CD52, an antigen found on the surface of normal and malignant lymphocytes.
Evolocumab
T9920CAS 1256937-27-5
Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9).
Infliximab
T9921CAS 170277-31-3
Infliximab is a humanized antibody against tumor necrosis factor α (TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis.
Matuzumab
T9922CAS 339186-68-4
Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR, frequently associated with the growth of blood vessels i...
Nimotuzumab
T9923CAS 828933-51-3
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR).
Obinutuzumab/afutuzumab
T9924CAS 949142-50-1
Obinutuzumab (GA101) a novel glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.
Ofatumumab
T9925CAS 679818-59-8
Ofatumumab is a fully human monoclonal antibody to CD20, which appears to inhibit early-stage B lymphocyte activation
Omalizumab
T9926CAS 242138-07-4
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE)
Panitumumab
T9927CAS 339177-26-3
Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor (EGFR).
Ranibizumab
T9928CAS 347396-82-1
Ranibizumab is an antibody fragment without the Fc portion and affinity-matured to more strongly bind VEGF-A
Ramucirumab
T9929CAS 947687-13-0
Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors.
Secukinumab
T9930CAS 875356-43-7
Secukinumab is a fully humanized, monoclonal anti-IL-17A antibody, and the first in its class to be approved by the US Food and Drug Administration for the trea...